Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the bottom line, with a Diluted EPS of -$0.34 vs. -$0.30 expected. Operating loss of $5.25M was significantly narrower than the -$14.25M consensus due to re-prioritized R&D spending following the February asset acquisition. However, cash reserves remain critical at just $0.8M, despite recent warrant inducements, highlighting an urgent need for additional capital to fund the upcoming TPST-4003 clinical trials.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tempest Therapeutics(TPST) the EPS is -0.34 (+83.57%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBIT
TBA--
-0.01B78.89%
----
EPSMiss expectations
-0.3483.57%
-0.385.51%
-0.04001.94%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf